Skip to content

Launch price: from €29.90 per box. Free delivery from 2 boxes.

FRENDEESIT

ophthalmic medicine

Ranibizumab

Anti-VEGF for macular degeneration and retinal edema. This molecule appears in 295 of the medicines we have indexed.

Our answerNothing to add

Do you need a supplement? No.

No supplement is warranted with this treatment. A varied diet remains the foundation.

Do you also take another treatment?

By the Layer Nutrition editorial teamHow the atlas classifies the 664 molecules

Class
ophthalmic medicine
Indexed medicines
295
Our answer
Nothing to add
Updated
October 2026
01The medication

What this medicine is for

It is a medicine in the “ophthalmic medicine” category. This ophthalmic medicine treats a condition of the eye.

In practice: Anti-VEGF for macular degeneration and retinal oedema. How to use it is decided case by case with the professional who prescribes it.

The name on your box may be here.

These names come from the public registers of 32 countries: the ANSM for France, the AEMPS for Spain, the AIFA for Italy, the HPRA for Ireland, Swissmedic for Switzerland, and the European Medicines Agency for the others.

Most widespread

  • XIMLUCI
  • BYOOVIZ
  • LUCENTIS
  • RANIVISIO
  • RIMMYRAH
  • RANLUSPEC
  • EPRUVY
  • REXATILUX
  • SUSVIMO
  • VISLYFA
See all names, country by countryHide the list by country

France5

  • BYOOVIZ
  • LUCENTIS
  • RANIVISIO
  • RIMMYRAH
  • XIMLUCI

Germany10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Spain8

  • BYOOVIZ
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • XIMLUCI

Italy7

  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • RIMMYRAH
  • XIMLUCI

United Kingdom1

  • XIMLUCI

Ireland10

  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • RIMMYRAH
  • VISLYFA
  • XIMLUCI
  • REXATILUX
  • SUSVIMO

Switzerland4

  • BYOOVIZ
  • LUCENTIS
  • RANIVISIO
  • XIMLUCI

Austria10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Belgium10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Bulgaria10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Cyprus10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Croatia10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Denmark10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Estonia10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Finland10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Greece10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Hungary10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Iceland10

  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • REXATILUX
  • RIMMYRAH
  • XIMLUCI
  • BYOOVIZ
  • RANLUSPEC
  • SUSVIMO
  • VISLYFA

Latvia10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Liechtenstein10

  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • REXATILUX
  • RIMMYRAH
  • XIMLUCI
  • BYOOVIZ
  • RANLUSPEC
  • SUSVIMO
  • VISLYFA

Lithuania10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Luxembourg10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Malta10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Norway10

  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • REXATILUX
  • RIMMYRAH
  • XIMLUCI
  • BYOOVIZ
  • RANLUSPEC
  • SUSVIMO
  • VISLYFA

Netherlands10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Poland10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Portugal10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Romania10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Slovakia10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Slovenia10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Sweden10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA

Czechia10

  • XIMLUCI
  • BYOOVIZ
  • EPRUVY
  • LUCENTIS
  • RANIVISIO
  • RANLUSPEC
  • REXATILUX
  • RIMMYRAH
  • SUSVIMO
  • VISLYFA
02Its place in the atlas

One answer out of three.

The atlas gives each molecule one of these three answers. Most call for nothing.

  • Our formula31 molecules
  • An active ingredient to consider59 molecules
  • Nothing to add574 moleculesincluding this one
Fig. 1The outlined square: Ranibizumab, one molecule among the 664 in the atlas. List: ANSM. Classification: Layer Nutrition.
03Other areas

In the same family

See the whole « Other areas » family

04Another treatment

Do you also take another treatment?

Type the name written on the box. The atlas gives you its answer.

For example Panadol, Doliprane or paracetamol.